Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2430975
Max Phase: Preclinical
Molecular Formula: C60H110N16O17
Molecular Weight: 1327.63
Molecule Type: Unknown
Associated Items:
ID: ALA2430975
Max Phase: Preclinical
Molecular Formula: C60H110N16O17
Molecular Weight: 1327.63
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](N)CCCCN)[C@@H](C)O
Standard InChI: InChI=1S/C60H110N16O17/c1-30(2)24-39(71-58(91)48(34(9)78)74-55(88)41(26-32(5)6)68-50(83)36(63)29-77)52(85)67-38(19-20-47(81)82)60(93)76-23-15-17-44(76)57(90)70-43(28-46(65)80)53(86)66-37(16-11-13-21-61)51(84)69-42(27-33(7)8)56(89)75-49(35(10)79)59(92)72-40(25-31(3)4)54(87)73-45(64)18-12-14-22-62/h30-45,48-49,77-79H,11-29,61-64H2,1-10H3,(H2,65,80)(H,66,86)(H,67,85)(H,68,83)(H,69,84)(H,70,90)(H,71,91)(H,72,92)(H,73,87)(H,74,88)(H,75,89)(H,81,82)/t34-,35-,36+,37+,38+,39+,40+,41+,42+,43+,44+,45+,48+,49+/m1/s1
Standard InChI Key: FCJCLCJIEXVSAI-YMNLNDONSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1327.63 | Molecular Weight (Monoisotopic): 1326.8235 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Hopping G, Kellock J, Caughey B, Daggett V.. (2013) Designed Trpzip-3 β-Hairpin Inhibits Amyloid Formation in Two Different Amyloid Systems., 4 (9): [PMID:24900756] [10.1021/ml300478w] |
Source(1):